Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIIB News Highlights
- BIIB's 30 day story count now stands at 25.
- Over the past 19 days, BIIB's stories per day has been in a clear uptrend, growing by about 0.90 per 2 days.
- DRUG, APYX and ARQT are the most mentioned tickers in articles about BIIB.
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
It’s Crunch Time for Biogen Stock. Data on Alzheimer’s Trial Are Due Tonight.Japan's Eisai , which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well. |
Biogen (BIIB) Down on Report of Death in Alzheimer's StudyInvestor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies. |
FOCUS-Rare success for Alzheimer's research unlocks hope for future therapiesThe first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer’s patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. |
UPDATE 1-Eisai shares plunge in Tokyo after report of death in Alzheimer's trialShares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died. A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday. Eisai's shares sank 6.2% to 8,988 yen, leading decliners on the benchmark Nikkei index, which closed 0.5% lower. |
Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drugJust weeks ago at the company’s headquarters, Haruo Naito, the 74-year-old chief executive of Japan’s Eisai, was feeling vindicated after almost four decades of trying to develop an Alzheimer’s drug. Ahead of the release of detailed information on Eisai’s new drug lecanemab, developed with Biogen, the company’s share price surged 60 per cent after results of a late-stage clinical trial showed that it slowed the progression rate of the memory-degenerating disease. Initial results published by Eisai in September raised hopes of a new treatment for a disease that pharmaceutical companies have spent billions of dollars over several decades researching, only to be disappointed by repeated failures. |
Eisai, Biogen Plunge After Report of Second Death in Groundbreaking Alzheimer’s Drug Trial(Bloomberg) -- Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsMusk Threatens War With Apple, Jeopardizing Vital RelationshipStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol |
Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trialShares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died. A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday. Eisai's shares sank 10% to 8,595 yen, leading decliners on the benchmark Nikkei index, which slid 0.5% in the morning session. |
7 Cheap Large-Cap Stocks to Buy Before They Surge HigherEven as they've delivered a solid performance so far this year, these seven cheap large-cap stocks to buy are still worth a look. |
Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A SetbackAxsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback. |
US STOCKS-Wall Street drops, weighed down by Apple and China worriesUS STOCKS-Wall Street drops, weighed down by Apple and China worries |